Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$86.93 USD

86.93
4,164,416

+0.73 (0.85%)

Updated Oct 11, 2024 03:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Radhika Pujara headshot

Skyworks (SWKS) & 3 Other Suppliers to Tap Uptick in iPhone Sales

Shares of Skyworks (SWKS) are skyrocketing post upbeat guidance and impressive Q1 performance driven by uptick in Apple's (AAPL) iPhone 12 sales. This positions other suppliers, including QRVO, JBL & SYNA, well to gain from the projected increase in iPhone 12 demand.

Skyworks' (SWKS) Q1 Earnings Top Estimates, Stock Up on Q2 View

Skyworks' (SWKS) fiscal first-quarter results gain from rapid 5G deployment and strength in overall broad markets.

Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings

Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.

Boston Scientific's (BSX) DBS System Gets FDA's Clearance

The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.

Boston Scientific (BSX) Enhances Core Business With Buyout

Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.

Sriparna Ghosal headshot

3 MedTech Stocks Up Above 50% That Might Lose Steam in 2021

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.

Boston Scientific's (BSX) SCS Systems Receives FDA's Nod

Boston Scientific's (BSX) WaveWriter Alpha portfolio of SCS Systems aims to widen the therapy options available for managing chronic pain.

Why Is Boston Scientific (BSX) Down 1.5% Since Last Earnings Report?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Trina Mukherjee headshot

3 Stocks to Capitalize on Promising Medical Products Industry

Despite the challenges triggered by the COVID-19 pandemic, higher demand for IVD products, digital influence and AI & Robotics are likely to lend support to the Zacks Medical - Products industry. ABT, BAX and RMD are well positioned to gain from the prospects.

Boston Scientific (BSX) in Focus: Stock Moves 7% Higher

Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Boston Scientific (BSX) Q3 Earnings Top, Margins Decline

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Boston Scientific (BSX) Tops Q3 Earnings and Revenue Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 48.00% and 5.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Products Q3 Earnings on Oct 28: BSX, CERN & More

In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.

Boston Scientific (BSX) Q3 Earnings to Grow on Vital Procedures

Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.

Analysts Estimate Boston Scientific (BSX) to Report a Decline in Earnings: What to Look Out for

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Align's (ALGN) ClinCheck Suite Now Commercially Available

Align Technology's (ALGN) ClinCheck treatment-planning software's commercial availability is expected to boost doctor performances due to ready availability of treatment plans.

Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View

Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.

Baxter Supports Findings of Ongoing COVID-19 Nutrition Study

The study, supported by Baxter (BAX) through an investigator-initiated grant, is the first analysis of longitudinal REE in critically ill, mechanically-ventilated COVID-19 patients.

Here's Why You Should Invest in AmerisourceBergen (ABC) Now

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

LHC Group (LHCG) and CHRISTUS Health Extend JV Partnership

LHC Group (LHCG) and CHRISTUS Health expand their partnership to boost home health services and hospice care.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

Investors' confidence is high in the Accuray (ARAY) stock, thanks to its solid prospects.

Here's Why You Should Retain AMN Healthcare (AMN) Stock Now

AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.

Allscripts Completes Sale of EPSi Business to Strata

Allscripts (MDRX) completes the sale of its EPSi business to Strata. Notably, the combination of two companies can reduce cost associated with healthcare.

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health

The Zacks Analyst Blog Highlights: Medtronic, Boston Scientific, DaVita, Accuray and Cardinal Health